News | Oncology Diagnostics | April 05, 2018

Indicated as a companion diagnostic for Lynparza (olaparib) for use in patients with metastatic inoperable or recurrent breast cancer

April 5, 2018 — Myriad Genetic Laboratories Inc. announced that the Japanese Ministry of Health, Labour and Welfare has granted manufacturing and marketing approval for Myriad’s BRACAnalysis Diagnostic System to be used as a companion diagnostic with the PARP inhibitor, Lynparza.  Lynparza is marketed by AstraZeneca and Merck, known as MSD outside the United States and Canada.

AstraZeneca and Merck are seeking approval of Lynparza in Japan for treating patients with BRCA-mutated metastatic breast cancer. BRACAnalysis is the first and only diagnostic test for a PARP inhibitor to receive regulatory approval in Japan. The test is marketed in the United States as BRCAnalysis CDx.

Currently there are about 40,000 patients with metastatic disease that would be eligible for BRACAnalysis testing in Japan, with an estimated 15,000 new cases of HER2-negative breast cancer diagnosed each year. Myriad will commercialize BRACAnalysis in exclusive partnership with the SRL Inc., a subsidiary of Miraca Group, and one of the largest laboratory service providers in Japan.

BRACAnalysis is a diagnostic system that classifies a patient’s clinically significant variants (DNA sequence variations) in the BRCA1 and BRCA2 genes. Variants are classified into one of the five categories — “Deleterious,” “Suspected Deleterious,” “Variant of Uncertain Significance,” “Favor Polymorphism” or “Polymorphism.” Once the classification is completed, the results are sent to medical personnel in Japan for determining the eligibility of patients for treatment with Lynparza.

BRACAnalysis CDx was approved by the U.S. Food and Drug Administration (FDA) in December 2014 for patients with advanced ovarian cancer, and again in January 2018 for patients with HER2-negative metastatic breast cancer.

For more information: www.myriad.com

 

Related Content

News | Breast Imaging

November 24, 2021 — Hologic Inc. will showcase its extensive portfolio of breast and skeletal health products, including ...

Time November 24, 2021
arrow
News | Flat Panel Displays

November 24, 2021 — The rise of digital imaging technology has quickly changed the way in which patient data are used ...

Time November 24, 2021
arrow
News | Mammography

November 23, 2021 — Siemens Healthineers has announced the U.S. Food and Drug Administration (FDA) clearance of two new ...

Time November 23, 2021
arrow
News | Women's Health

November 22, 2021 — Intrauterine contraceptive devices (IUDs) appear to have systemic effects on the body like those of ...

Time November 22, 2021
arrow
News | Breast Imaging

November 16, 2021 — Patients with two out of the three most common types of advanced breast cancer now have an average ...

Time November 16, 2021
arrow
News | Mammography

November 15, 2021 — Volpara Health and leading mammography education provider, Mammography Educators LLC, have expanded ...

Time November 15, 2021
arrow
News | Artificial Intelligence

November 11, 2021 — CureMetrix Inc., a global healthcare technology company that develops AI-based software for ...

Time November 11, 2021
arrow
News | Breast Density

November 10, 2021 — DenseBreast-info.org (DB-I) commemorates the 10-year anniversary of the FDA’s National Mammography ...

Time November 10, 2021
arrow
Feature | Breast Density | By Robert L. Bard, M.D. DABR, FASL and Noelle Cutter, Ph.D.

Prologue In 2014, Imaging Technology News (ITN) introduced breast cancer survivor-turned-crusader Nancy Cappello, Ph.D ...

Time November 09, 2021
arrow
News | Enterprise Imaging

November 3, 2021 — “Brilliant workflows. Made for you.” is the key theme for international medical imaging IT and ...

Time November 03, 2021
arrow
Subscribe Now